* iAbra's Virolens test is said to provide coronavirus results in 20 seconds
* Test had a three-week trial at
* Could replace the polymerase chain reaction (PCR) mouth swab tests
*
One of the best kept COVID-19 secrets percolating overseas that has not yet hit mainstream media is how
The new Virolens test, which is said to provide results in 20 seconds, launched on Wednesday following a three-week trial at
The saliva test, developed with iAbra, a Bedfordshire-based technology company founded in 2010,
SPEED ADVANTAGE
Virolens is a machine learning holographic microscope that provides a self-administered test using a single use cartridge.
It's main advantage appears to be speed. The Virolens test takes just 20 seconds to administer, with perhaps a similar amount of time needed to check results and change the cartridge for the next test. By contrast, Geneme and Mologic take approximately 30 minutes and 10 minutes respectively to produce results, so the advantage in dealing with many more arriving air passengers is clear.
'It is still fairly early in the process, with Virolens undergoing further trials alongside competing solutions, but the situation is said to be developing rapidly,' said Numis analyst
Internal testing of the system has shown 99.8% sensitivity and 96.7% specificity. It has also been trialed at
GLOBAL TESTING STATISTICS
According to Our World in Data, the world is on pace to do over a billion tests by the end of the year. With the ease of accurate 20 second tests compared to recent tests that delivered results in days or even a week+, it can only accelerate the amount of tests administered due to people being tested multiple times, especially if traveling.
Besides the health of every country's citizens, the next biggest concern is getting the economy back on track, especially the travel, sporting event and restaurant industries. Having a means of testing someone even faster than the results from a pregnancy test is critical to getting the world back to a state of normality.
As many scientists have said, this virus is not going away anytime soon, testing will have to be administered often so that traveling can go back to normal, children can go back to school and people can get back to work. Inevitably, there will be 2nd waves this fall, as countries like
INVESTMENT SUMMARY
These news articles are plastered all over the
Looking at the charts, INTC has struggled a bit, but
About EmergingGrowth.com
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.
This article was written by a guest contributor and solely reflects his/her opinions. All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. The statements in this article are not that of, nor have they been verified by, or are the opinion of, EmergingGrowth.com. All material is for informational purposes only, and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. Please consult an investment professional before investing in anything viewed within.
In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
Contact Information:
Media Contact
email: Info@EmergingGrowth.com
+1(305) 330-1985
SOURCE: EmergingGrowth.com
CONTACT: Contact Information:
Media Contact
email: Info@EmergingGrowth.com
+1(305) 330-1985
SOURCE: EmergingGrowth.com
.
(C) 2020 M2 COMMUNICATIONS, source